Tesla
Dividend Calendar
Stock Rankings
ETF Rankings
Crypto Rankings
See Graham's ranking
4.0
Sarepta Therapeutics Inc. (SRPT) operates in the healthcare sector within the biotechnology industry, focusing on the development of genetic therapies and treatments for rare diseases, particularly muscular dystrophies.
The company specializes in RNA-based therapeutics and gene therapy solutions.
Its main areas of activity include:
• Therapies for Duchenne muscular dystrophy (DMD).
• Development of gene therapies.
• RNA-based medicines.
• Research and development for rare diseases.
• Advanced biotechnology clinical programs.
Sarepta primarily operates in the United States, with global clinical research activities and partnerships.
Key factors influencing its business include regulatory approvals, clinical trial outcomes, research costs, scientific advancements and competition within the biotechnology sector.
Shares of Sarepta Therapeutics Inc. trade on the Nasdaq under the ticker SRPT.
History and Development
Sarepta was founded in 1980 in the United States, initially focused on antiviral drug development.
Over time, the company shifted its strategy toward rare diseases, particularly muscular dystrophies.
It later built a portfolio centered on Duchenne therapies, becoming a key player in this niche.
In 1997, Sarepta completed its Initial Public Offering (IPO) on the Nasdaq, supporting its research and development efforts.
In recent years, the company has advanced its gene therapy programs and expanded its treatment pipeline, with a continued focus on innovation and clinical development.
Additional Information
Sarepta Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.10 Billions, with shareholders equity totaling $1.51 Billion.
The company employs approximately 866 people and operates in the Services sector, within the Commercial Services industry.
Over the past 12 months, Sarepta Therapeutics Inc. reported $2.18 Billions in revenue, generating net income of $65.05 Millions.
Key financial metrics include a P/E ratio of 32.21, a price-to-book (P/B) ratio of 1.39, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker SRPT.
